Deborah Kacanek1, Paige L Williams1, Gloria Mayondi2, Penny Holding3, Jean Leidner4, Kebaiphe Moabi2, Vicki Tepper5, Sharon Nichols6, Joseph Makhema2, Haruna Jibril7, Tebogo Madidimalo7, Roger Shapiro2,8,9, Shahin Lockman2,9,10, Betsy Kammerer11. 1. Department of Biostatistics, Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA. 2. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 3. Identitea Consulting, Nairobi, Kenya. 4. Goodtables Consulting, Norman, OK. 5. Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD. 6. Department of Neurosciences, University of California San Diego, San Diego, CA. 7. Botswana Ministry of Health and Wellness, Gaborone, Botswana. 8. Beth Israel Deaconess Medical Center, Boston, MA. 9. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA. 10. Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA. 11. Department of Psychiatry, Boston Children's Hospital, Boston, MA.
Abstract
BACKGROUND: In utero exposure to nucleoside reverse transcriptase inhibitor (NRTI)-containing antiretroviral treatment (ART) regimens may be associated with poor neurodevelopmental functioning in children of HIV-infected mothers. We investigated neurodevelopmental outcomes of HIV-exposed uninfected (HEU) children of HIV-infected women enrolled in a randomized trial of abacavir/zidovudine/lamivudine (triple-NRTI regimen) vs. lopinavir/ritonavir/zidovudine/lamivudine [dual-NRTI + protease inhibitor (PI) regimen]. SETTING: The Mma Bana randomized trial was conducted in urban and rural sites in Botswana. METHODS: The Mma Bana study randomized HIV-infected pregnant women with CD4 ≥200 cells per mm to atriple-NRTI vs. dual-NRTI + PI regimen from 26- to 34-week gestation through planned weaning at 6-month postpartum. Partway through the study, neurodevelopmental assessments were added at 24 months of age, including the Developmental Milestones Checklist, the Bayley Scales of Infant and Toddler Development third edition, Ten Questions Questionnaire, and Profile of Social Emotional Development. We evaluated differences in mean scores between the 2 arms using unadjusted and adjusted linear regression. RESULTS: A total of 197 HEU infants (48% male) completed a neurodevelopmental assessment (101 in triple-NRTI arm and 96 in dual-NRTI + PI-exposed arm). Mean values for all neurodevelopmental outcomes were similar for children of mothers randomized to either ART regimen, with no significant differences in either unadjusted or adjusted models (estimated effect sizes ranging from -0.12 to 0.14). CONCLUSIONS:Neurodevelopmental outcomes in 24-month-old HEU children of HIV-infected mothers with baseline CD4 ≥200 were similar in those randomized to a dual-NRTI + PI-based vs. a triple-NRTI-based ART regimen, suggestive of lack of short-term toxicity. Monitoring of long-term toxicity and newer regimens is warranted.
RCT Entities:
BACKGROUND: In utero exposure to nucleoside reverse transcriptase inhibitor (NRTI)-containing antiretroviral treatment (ART) regimens may be associated with poor neurodevelopmental functioning in children of HIV-infected mothers. We investigated neurodevelopmental outcomes of HIV-exposed uninfected (HEU) children of HIV-infectedwomen enrolled in a randomized trial of abacavir/zidovudine/lamivudine (triple-NRTI regimen) vs. lopinavir/ritonavir/zidovudine/lamivudine [dual-NRTI + protease inhibitor (PI) regimen]. SETTING: The Mma Bana randomized trial was conducted in urban and rural sites in Botswana. METHODS: The Mma Bana study randomized HIV-infected pregnant women with CD4 ≥200 cells per mm to a triple-NRTI vs. dual-NRTI + PI regimen from 26- to 34-week gestation through planned weaning at 6-month postpartum. Partway through the study, neurodevelopmental assessments were added at 24 months of age, including the Developmental Milestones Checklist, the Bayley Scales of Infant and Toddler Development third edition, Ten Questions Questionnaire, and Profile of Social Emotional Development. We evaluated differences in mean scores between the 2 arms using unadjusted and adjusted linear regression. RESULTS: A total of 197 HEU infants (48% male) completed a neurodevelopmental assessment (101 in triple-NRTI arm and 96 in dual-NRTI + PI-exposed arm). Mean values for all neurodevelopmental outcomes were similar for children of mothers randomized to either ART regimen, with no significant differences in either unadjusted or adjusted models (estimated effect sizes ranging from -0.12 to 0.14). CONCLUSIONS: Neurodevelopmental outcomes in 24-month-old HEU children of HIV-infected mothers with baseline CD4 ≥200 were similar in those randomized to a dual-NRTI + PI-based vs. a triple-NRTI-based ART regimen, suggestive of lack of short-term toxicity. Monitoring of long-term toxicity and newer regimens is warranted.
Authors: Ariane Alimenti; John C Forbes; Tim F Oberlander; Deborah M Money; Ruth E Grunau; Michael P Papsdorf; Evelyn Maan; Lesley J Cole; David R Burdge Journal: Pediatrics Date: 2006-08-28 Impact factor: 7.124
Authors: S Blanche; M Tardieu; P Rustin; A Slama; B Barret; G Firtion; N Ciraru-Vigneron; C Lacroix; C Rouzioux; L Mandelbrot; I Desguerre; A Rötig; M J Mayaux; J F Delfraissy Journal: Lancet Date: 1999-09-25 Impact factor: 79.321
Authors: Lindsey M Locks; Karim P Manji; Roland Kupka; Enju Liu; Rodrick Kisenge; Christine M McDonald; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Date: 2016-11-07 Impact factor: 4.406
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Paige L Williams; Miguel Marino; Kathleen Malee; Susan Brogly; Michael D Hughes; Lynne M Mofenson Journal: Pediatrics Date: 2010-01-18 Impact factor: 7.124
Authors: Susan B Brogly; Nathalie Ylitalo; Lynne M Mofenson; James Oleske; Russell Van Dyke; Marilyn J Crain; Mark J Abzug; Michael Brady; Patrick Jean-Philippe; Michael D Hughes; George R Seage Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Miriam C Poirier; Rao L Divi; Lena Al-Harthi; Ofelia A Olivero; Vi Nguyen; Brettania Walker; Alan L Landay; Vernon E Walker; Manhattan Charurat; William A Blattner Journal: J Acquir Immune Defic Syndr Date: 2003-06-01 Impact factor: 3.731
Authors: Catherine J Wedderburn; Ella Weldon; Cesc Bertran-Cobo; Andrea M Rehman; Dan J Stein; Diana M Gibb; Shunmay Yeung; Andrew J Prendergast; Kirsten A Donald Journal: Lancet Child Adolesc Health Date: 2022-04-26